Pelthos Therapeutics vs Scilex
PTHS and SCLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PTHS and SCLX compare
Pelthos Therapeutics is the larger company, worth 2.6 times as much as Scilex ($35.9M against $13.7M).
Pelthos Therapeutics keeps more of each dollar of sales as profit, with a net margin of −152% compared with −1470% at Scilex.
Pelthos Therapeutics scores higher on the StockData Score (2 against 1 for Scilex), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PTHS | SCLX |
|---|---|---|
| Size and price | ||
| Market cap | $35.9M | $13.7M |
| Share price | $9.39 | $1.61 |
| Change, 1 year | −72.4% | −91.4% |
| Change, 5 years | – | −99.5% |
| Beta (5Y) | – | 0.82 |
| Employees | 92 | 34 |
| StockData Score | ||
| Total score | 2 (better) | 1 |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 0 |
| Health score | 1 (better) | 0 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.7× | 0.4× (better) |
| FCF yield | −90.6% | – |
| Growth | ||
| Revenue growth (TTM) | – | −28.5% |
| Revenue growth, 5Y average | – | 5.1% |
| Profitability | ||
| Gross margin | 83.2% | 161% (better) |
| Operating margin | −102% (better) | −1136% |
| Net margin | −152% (better) | −1470% |
| FCF margin | −63.5% | – |
| Return on equity | −300% | – |
| Return on invested capital | −408% | – |
| Financial health | ||
| Interest coverage | −6.3× (better) | −22.2× |
| Current ratio | 1.78 (better) | 0.07 |
| Altman Z-score | −1.86 (better) | −12.74 |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 35.6% | 9.8% |
| Insider net buying, 12 months | $794K (better) | −$12.8M |
Go deeper
- PTHS stock overview
- PTHS income statement
- PTHS valuation and score
- SCLX stock overview
- SCLX income statement
- SCLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.